SAN DIEGO–(BUSINESS WIRE)–Persephone Biosciences Inc., a biotechnology company aiming to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome, today announced that the company will present and host 1×1 meetings with investors at Chardan’s 4th Annual Metagenomics and Microbiome Medicines Summit.
- The company’s presentation will take place virtually on March 1, 2022, at 4:00 p.m. ET.
- Dr. Stephanie Culler, Persephone Biosciences’ co-founder and CEO, will also participate in the panel titled, “Great Debate – Is the term ‘Microbiome’ Drug Development Now Passé?” at 3:15 p.m. ET.
About Persephone Biosciences
Persephone aims to develop better treatment outcomes and improve disease prevention through a greater understanding of the microbiome. Persephone’s technology platform is based on diverse and inclusive, population-scale, observational clinical trials in conjunction with advanced multi-omics analyses and machine learning with the aim to probe the complex interaction between microbes and the immune system. Persephone develops precision immunotherapies utilizing synthetic biology and companion diagnostics for unmet needs and more equitable treatment outcomes.
For more information, visit www.persephonebiosciences.com
Contacts
Dr. Stephanie Culler
CEO and Co-founder
Persephone Biosciences, Inc.
investors@persephonebiosciences.com
Laurence Watts
Managing Director
Gilmartin Group, LLC.
laurence@gilmartinir.com
Media Contacts:
Evan Wicker, Ph.D.
Russo Partners, LLC
evan.wicker@russopartnersllc.com
212-845-4235
Olipriya Das, Ph.D.
Russo Partners, LLC
Olipriya.Das@russopartnersllc.com
646-942-5588